Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Equity Average (2016 - 2025)

Cardiff Oncology's Equity Average history spans 14 years, with the latest figure at $47.1 million for Q4 2025.

  • For Q4 2025, Equity Average fell 28.84% year-over-year to $47.1 million; the TTM value through Dec 2025 reached $47.1 million, down 28.84%, while the annual FY2025 figure was $64.2 million, 15.95% down from the prior year.
  • Equity Average for Q4 2025 was $47.1 million at Cardiff Oncology, down from $53.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $137.0 million in Q4 2021 and bottomed at $47.1 million in Q4 2025.
  • The 5-year median for Equity Average is $86.9 million (2023), against an average of $92.5 million.
  • The largest annual shift saw Equity Average soared 1780.44% in 2021 before it plummeted 38.12% in 2024.
  • A 5-year view of Equity Average shows it stood at $137.0 million in 2021, then decreased by 19.86% to $109.8 million in 2022, then tumbled by 32.79% to $73.8 million in 2023, then fell by 10.32% to $66.2 million in 2024, then fell by 28.84% to $47.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Equity Average are $47.1 million (Q4 2025), $53.7 million (Q3 2025), and $64.7 million (Q2 2025).